US FDA approved new drug Radicava that contains active pharmaceutical ingredient edaravone for the treatment of amyotrophic lateral sclerosis (ALS). Radicava/edaravone is categorized as nootropic agent that helps in recovering cerebral damage or degeneration occurs as result of cerebral ischemia, cerebral infarction or any other disorder.
Amyotrophic lateral sclerosis (ALS) also termed as Lou Gehrig's disease is a rare kind of neuronal problem associated with neuronal death. Neuron is basic unit of nervous system that regulates neuronal transmission required for coordination between body muscles and brain. Amyotrophic lateral sclerosis (ALS) most commonly affects motor neurons that controls body motor functions like driving, walking, speech, breathing etc.
Exact underlying cause is still unknown but many researchers assume that genetic predisposition is key factor in pathogenesis of such disorders. Some other causes that associated with Amyotrophic lateral sclerosis (ALS) are head injury, trauma and branched-chain amino acids enriched diet that induce cellular hyperexcitability. Lesions inside frontotemporal lobes may also be a cause of Amyotrophic lateral sclerosis (ALS).
Initially, it is started as muscular weakness and atropy (decrease in number of cells) . At this time symptoms are very insignificant to feel and patient may overlook these symptoms. when disease progress completely then patine may feel difficulty in walking, speech problems, difficulty with tasks requiring manual dexterity such as buttoning a shirt, writing, or turning a key in a lock may be experienced and muscle spasticity.
Radicava/edaravone Side effects
According to data provided by health authorities following side effects were observed during clinical trials
- Shortness of breath
- Sodium bisulfite induced allergy
- Gait disturbance
- Loss of appetite
- Sleep disturbance
US FDA approved this drug for the treatment of amyotrophic lateral sclerosis (ALS) to show to slow down functional decline. Radicava/edaravone is free-radical scavenger that is aimed to suppress oxidative degeneration which is a major factor in amyotrophic lateral sclerosis (ALS).
This drug is formulated in a single dose polypropylene bag with potency of 30mg/100ml. However, standard dosage frequency of this drug is 60mg as intravenous infusion (IV) over 60 minutes once a day for 14 days followed by a 14-day drug-free period.
This drug is administered by your healthcare practitioner (HCP), which usually means:
- It may comes under special items category.
- You cannot fill this prescription in a regular pharmacy. Your doctor, hospital, or clinic will provide this medication because of possible complications or other issues.
- This drug is likely to be covered under your medical benefit if you have insurance.